Topoisomerase II levels and drug response in small cell lung cancer

International Journal of Oncology

Volumn 10, Issue 5, 1997, Pages 885-893

  Campling, B G ^a,b   Baer, K A ^a   Gerlach, J H ^a   Lam, Y M ^a   Cole, S P C ^a   Mirski, S E L ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b Cancer Centre of South Eastern Ontario   (Canada)

Author keywords

drug resistance; small cell lung cancer; topoisomerase II

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; AMSACRINE; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; MENOGARIL; MESSENGER RNA; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PROCARBAZINE; TENIPOSIDE; VINBLASTINE; VINCRISTINE;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TISSUE LEVEL;

EID: 0030902435     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.5.885     Document Type: Article

References (12)

1. Ling V: P-glycoprotein and resistance to anticancer drugs. Cancer 69: 2603-2609, 1992.
2. Reeve JG, Rabbitts PH and Twentyman PR: Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. Br J Cancer 60: 339-342, 1989.
3. Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y and Saijo N: Characterization of an etoposide-resistant human small cell lung cancer cell line. Cancer Chemother Pharmacol 26: 313-317, 1990.
4. Holzmayer TA, Hilsenbeck S, von Hoff DD and Roninson IB: Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small cell lung carcinomas. J Natl Cancer Inst 84: 1486-1491, 1992.
5. Poupon MF, Arvelo F, Goguel AF, Bourgeois Y, Jacrot M, Hanania N, Arriagada R and Le Chevalier T: Response of small cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst 85: 2023-2029, 1993.
6. Campling BG, Young LC, Baer KA, Lam Y-M, Deeley RG, Cole SPC and Gerlach JH: Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 3: 115-122, 1997.
7. Nitiss JL and Beck WT: Antitopoisomerase drug action and resistance. Eur J Cancer 32A: 958-966, 1996.
8. Nelson EM, Tewey KM and Liu LF: Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81: 1361-1365, 1984.
9. Tewey KM, Chen GL, Nelson EM and Liu LF: Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 226: 466-468, 1984.
10. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM and Liu LF: Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 13560-13566, 1984.
11. Cole SPC: Multidrug resistance in human lung cancer and topoisomerase II. In: Lung Cancer. Principles and Practice. Pass HI, Mitchell J, Johnson DH and Turrisi AT (eds). J.B. Lippincott, Company, Philadelphia, pp169-204, 1996.
12. Deffie AM, Bosman DJ and Goldenberg GJ: Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. Cancer Res 49: 6879-6882, 1989.